Literature DB >> 16719786

Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors.

Franco Chimenti1, Adriana Bolasco, Fedele Manna, Daniela Secci, Paola Chimenti, Arianna Granese, Olivia Befani, Paola Turini, Roberto Cirilli, Francesco La Torre, Stefano Alcaro, Francesco Ortuso, Thierry Langer.   

Abstract

The present report provides a extended study of the chemistry, the inhibitory activity against monoamino oxidases (MAO), and molecular modeling including the 3D-QSAR hypothesis of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives. Four series of about eighty novel pyrazoline derivatives were prepared and investigated for their ability to inhibit the activity of the A and B isoforms of MAO selectively. Most of the new synthesized compounds proved more reversible, potent, and selective inhibitors of MAO-A than of MAO-B, and could be taken into account to develop the search further in this field, knowing that reversible and selective MAO-A inhibitors are used as antidepressant and antianxiety drug. The 30 most active compounds show inhibitory activity on MAO-A in the 8.6 x 10(-8) - 9.0 x 10(-9)M range. Moreover, it should be pointed out that for most of them a high IC(50) > or = 10(-9)M value is associated with a high A-selectivity (Selectivity Index MAO-B/MAO-A in the 10,000-16,250 range). Furthermore, due to the presence of a chiral centre at the C5 position of the pyrazole moiety, we performed the semi-preparative chromatographic enantioseparation of the most potent, selective, and chiral compounds. The separated enantiomers were then submitted to in vitro biological evaluation, and from the results of these experiments it has been possible to point out a difference in inhibiting the two isoforms selectively between the racemic mixture and the single enantiomers. The molecular modeling work was carried out combining the Glide docking approach with CoMFA with the aim to rationalize the structure-activity relationships of each pyrazoline inhibitor toward MAO-A and MAO-B isoforms and to derive a suitable selectivity model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16719786     DOI: 10.2174/092986706776872907

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

Review 1.  Predicting monoamine oxidase inhibitory activity through ligand-based models.

Authors:  Santiago Vilar; Giulio Ferino; Elias Quezada; Lourdes Santana; Carol Friedman
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

2.  Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives.

Authors:  Umut Salgin-Gökşen; Samiye Yabanoğlu-Çiftçi; Ayşe Ercan; Kemal Yelekçi; Gülberk Uçar; Nesrin Gökhan-Kelekçi
Journal:  J Neural Transm (Vienna)       Date:  2013-01-30       Impact factor: 3.575

3.  3D-QSAR design of new escitalopram derivatives for the treatment of major depressive disorders.

Authors:  Speranta Avram; Catalin Buiu; Daniel M Duda-Seiman; Corina Duda-Seiman; Dan Mihailescu
Journal:  Sci Pharm       Date:  2010-05-05

Review 4.  Heterocyclic Compounds: Pharmacology of Pyrazole Analogs From Rational Structural Considerations.

Authors:  Rafael Fernades Costa; Larissa Córdova Turones; Keilah Valéria Naves Cavalcante; Ismael Aureliano Rosa Júnior; Carlos Henrique Xavier; Lucimar Pinheiro Rosseto; Hamilton Barbosa Napolitano; Patrícia Ferreira da Silva Castro; Marcos Luiz Ferreira Neto; Gustavo Mota Galvão; Ricardo Menegatti; Gustavo Rodrigues Pedrino; Elson Alves Costa; José Luis Rodrigues Martins; James Oluwagbamigbe Fajemiroye
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

5.  4-(2H-1,3-Benzodioxol-5-yl)-1-(4-methyl-phenyl)-1H-pyrazol-5-amine.

Authors:  Nilesh N Gajera; Mukesh C Patel; Mukesh M Jotani; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-04-17

6.  A monoclinic polymorph of 4-(2H-1,3-benzodioxol-5-yl)-1-(4-methyl-phen-yl)-1H-pyrazol-5-amine.

Authors:  Mukesh M Jotani; Nilesh N Gajera; Mukesh C Patel; Herman H Y Sung; Edward R T Tiekink
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-09-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.